0001179110-14-012955.txt : 20140815 0001179110-14-012955.hdr.sgml : 20140815 20140815161032 ACCESSION NUMBER: 0001179110-14-012955 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140814 FILED AS OF DATE: 20140815 DATE AS OF CHANGE: 20140815 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACCELERON PHARMA INC CENTRAL INDEX KEY: 0001280600 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 128 SYDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-9200 MAIL ADDRESS: STREET 1: 128 SYDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kumar Ravindra CENTRAL INDEX KEY: 0001586835 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36065 FILM NUMBER: 141046616 MAIL ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2014-08-14 0 0001280600 ACCELERON PHARMA INC XLRN 0001586835 Kumar Ravindra 128 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 VP & Chief Scientific Officer Common Stock 2014-08-14 4 S 0 2000 29.85 D 33890 D Common Stock 2014-08-14 4 M 0 5000 5.88 A 38890 D Common Stock 2014-08-14 4 S 0 7000 30.00 D 31890 D Option to Purchase Common Stock 5.88 2014-08-14 4 M 0 5000 5.88 D 2019-12-02 Common Stock 5000 10000 D The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.57 to $30.06, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange Commission, upon request, full information regrding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant. /s/ John Quisel, as attorney-in-fact for Ravindra Kumar 2014-08-15